A randomized clinical trial of valacyclovir in multiple sclerosis

Abstract

Objective: The human Herpesvirus type-6 (HHV-6) has been implicated in multiple sclerosis (MS). Valacyclovir is an antiviral agent with an excellent safety profile. A two-year, placebo-controlled, double-blind study was conducted to (1) ascertain if high-dose, prolonged treatment with valacyclovir would be safe and (2) observe if valacyclovir would delay the progression of MS clinically or by magnetic resonance imaging (MRI). Design/methods: Fifty-eight patients were stratified as to severity and randomly assigned to receive valacyclovir (3000 mg/day) or placebo for a period of two years. Patients were followed clinically over the two-year period by means of the Expanded Disability Status Scale (EDSS), the Ambulation Index (AI) and brain MRI scans. Patients underwent routine lab studies every three months. Patients continued on the medication for two years unless they had a sustained progression or repeated exacerbations. Results: No patient discontinued the study due to side effects or toxicity. In Relative Ranking of Progression, time to first attack, attack rate, and time to withdrawal there were trends (but not statistically significant) toward drug effect over placebo in the Severe clinical category. MRI evaluation showed no significant drug effect. Conclusions: Although not statistically significant, positive trends were detected for acyclovir by clinical measures, but not by MRI.

Keywords

antiviral drugs clinical trials herpesvirus 6 human antivirals multiple sclerosis (MS)

Get full access to this article

View all access options for this article.

References

Compston A , Sadovnick AD. Epidemiology and genetics of multiple sclerosis . Curr Opin Neurol Neurosurg 1992; 5: 175-181 .

Alvord EC Jr , Jahnke U , Fischer EH , Kies MW , Driscoll BF , Compston DA. The multiple causes of multiple sclerosis: the importance of age of infections in childhood . J Child Neurol 1987; 2: 313-321 .

Gale CR , Martyn CN. Migrant studies in multiple sclerosis . Prog Neurobiol 1995; 47: 425-448 .

Dean G. The multiple sclerosis problem . Sci Am 1970; 223: 40-46 .

Kurtzke JF , Hyllested K. Multiple sclerosis in the Faroe Islands. III. An alternative assessment of the three epidemics . Acta Neurol Scand 1987; 76: 317-339 .

Banks T , Rouse B.

Herpesviruses-immune escape artists?

Clin Inf Dis 1992; 14: 933-941 .

Herndon RM. Herpessviriuses in multiple slcerosis . Arch Neurol 1996; 53: 123-124 .

Wandinger K , Jabs W , Siekhaus A , Bubel S , Trillenberg P , Wagner H et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS . Neurology 2000; 55: 178-184 .

Ascherio A , Munger KL , Lennette ET , Spiegelman D , Hernán MA , Olek MJ et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study . JAMA 2001; 286: 3083-3088 .

10.

Ferrante P , Mancuso R , Pagani E , Guerini FR , Calvo MG , Sarasella M et al. Molecular evidences for a role of HSV-1 in multiple sclerosis clinical acute attack . J Neurovirol 2000; 6 (Suppl 2): S109-S114 .

11.

Challoner PB , Smith KT , Parker JD , Macleod DL , Coulter SN , Rose TM et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis . PNAS 1995; 92: 7440-7444 .

12.

Yamanishi K , Okuno T , Shiraki, Takahashi M , Kondo T , Asano Y et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum . Lancet 1988; 1: 1065-1067 .

13.

Friedman JE , Lyons MJ , Cu G , Ablashi DV , Whitman JE , Edgar M et al. The association of the human herpesvirus-6 and MS . Mult Scler 1999; 5: 355-362 .

14.

Sola P , Merelli E , Marasca R , Poggi M , Luppi M , Montorsi M et al. Human herpesvirus 6 and multiple sclerosis:survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction . J Neurol, Neurosurg & Psych 1992; 56: 917-919 .

15.

Ablashi DV , Lapps W , Kaplan M , Whitman JE , Richert JR , Pearson GR. Human Herpesvirus-6 (HHV-6) infection in multiple sclerosis: a preliminary report . Multiple Sclerosis 1998; 4: 490-496 .

16.

Soldan SS , Berti R , Salem N , Secchiero P , Flamand L , Calabresi PA et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA . Nature Med 1997; 12: 1394-1397 .

17.

Pellett PE , Sanchez-Martinez D , Dominguez G , Black JB , Anton E , Greenmoyer C et al. A strongly immunoreactive virion protein of human herpesvirus 6 variant B strain Z29: identification and characterization of the gene and mapping of a variant-specific monoclonal antibody reactive epitope . Virol 1993; 195: 521-531 .

18.

Sanders VJ , Felisan S , Waddell A , Tourtellotte WW. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction . J Neurovirol 1966; 2: 249-258 .

19.

Novoa LJ , Nagra RM , Nakawatase T , Edwards-Lee T , Tourtel-lotte WW , Cornford ME. Fulminant demyelinating encephalomyelitis associated with productive HHV-6 infection in an immunocompetent adult . J Med Virol 1997; 52: 301-308 .

20.

Bech E , Lycke J , Gadeberg P , Hansen HJ , Malmestrom C , Andersen O et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS . Neurology 2002; 58: 31-36 .

21.

Lycke J , Svennerholm B , Hjelmquist E , Frisen L , Badr G , Andersson M et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study . J Neurol 1996; 243: 214-224 .

22.

Martin C , Enbom M , Soderstrom M , Fredrikson S , Dahl H , Lycke J et al. Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis . Acta Neurol Scand 1997; 95: 280-283 .

23.

Enbom M , Wang FZ , Fredrikson S , Martin C , Dahl H , Linde A. Similar humoral and cellular immunological reactivities to human herpesvirus 6 in patients with multiple sclerosis and controls . Clin Diag Lab Immunol 1999; 6: 545-549 .

24.

Readon JE , Spector T. Acyclovir. Mechanism of antiviral action and potentiation by ribonucleotide reductase inhibitors . Adv Pharmacol 1991; 22: 1-27 .

25.

Littler E , Stuart AD , Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir . Nature 1992; 358: 160-162 .

26.

Wagstaff AJ , Faulds D , Goa KL. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy . Drugs 1994; 47: 153-205 .